Literature DB >> 28769008

Ketamine Alleviates Depressive-Like Behaviors via Down-Regulating Inflammatory Cytokines Induced by Chronic Restraint Stress in Mice.

Sijie Tan1, Yan Wang1, Ke Chen2, Zhifeng Long1, Ju Zou3.   

Abstract

The purpose of the present study was to investigate whether ketamine's rapid antidepressant effects were associated with its anti-inflammatory actions and to explore the underlying molecular mechanism. Depressive-like behaviors was induced in mice using chronic restraint stress (CRS) method. Anti-depressive effects of ketamine were evaluated by forced swimming tests (FST) and sucrose preference test (SPT). Subsequently, brain tissue was harvested to investigate inflammatory response in the hippocampus via investigating reactive microglia numbers, serum cytokines levels and the toll-like receptor type 4 (TLR4)/p38 mitogen-activated protein kinase (MAPK) pathway. CRS exposure caused depressive-like behaviors in mice, which was associated with increased pre-inflammatory cytokines (interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6) levels, reactive microglia numbers and up-regulated regulatory molecules such as TLR4/p38 and P2X7 receptor in hippocampus. Such neurobehavioral and biochemical abnormalities were normalized by ketamine treatment. CRS-induced depression-like behaviours are associated with activation of hippocampal inflammatory response, whereas down-regulation of pro-inflammatory cytokines may contribute to ketamine's antidepressant effects in mice.

Entities:  

Keywords:  P2X7; depression; inflammation; ketamine; toll-like receptor type 4 (TLR4)

Mesh:

Substances:

Year:  2017        PMID: 28769008     DOI: 10.1248/bpb.b17-00131

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  36 in total

Review 1.  Neurobiology of Resilience: Interface Between Mind and Body.

Authors:  Flurin Cathomas; James W Murrough; Eric J Nestler; Ming-Hu Han; Scott J Russo
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

2.  Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice.

Authors:  Songnian Fu; Jiangtao Wang; Chenguang Hao; Haihong Dang; Sheng Jiang
Journal:  Psychopharmacology (Berl)       Date:  2019-03-07       Impact factor: 4.530

3.  Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.

Authors:  Anindya Bhattacharya; Brian Lord; Jan-Sebastian Grigoleit; Yingbo He; Ian Fraser; Shannon N Campbell; Natalie Taylor; Leah Aluisio; Jason C O'Connor; Mariusz Papp; Christa Chrovian; Nicholas Carruthers; Timothy W Lovenberg; Michael A Letavic
Journal:  Neuropsychopharmacology       Date:  2018-07-09       Impact factor: 7.853

Review 4.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

5.  The Sustained Antidepressant Effects of Ketamine Are Independent of the Lateral Habenula.

Authors:  Xuelong Zhou; Chenjing Zhang; Jiamin Miao; Ziyang Chen; Hongquan Dong; Cunming Liu
Journal:  J Neurosci       Date:  2021-03-04       Impact factor: 6.167

6.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

7.  Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.

Authors:  Edem Ekpenyong Edem; Collins-Kevin Chukwudi Anyanwu; Kate Eberechukwu Nebo; Elizabeth Toyin Akinluyi; Adedamola Adediran Fafure; Azeez Olakunle Ishola; Linus Anderson Enye
Journal:  Psychopharmacology (Berl)       Date:  2021-11-18       Impact factor: 4.530

Review 8.  Inflaming sex differences in mood disorders.

Authors:  Jennifer R Rainville; Georgia E Hodes
Journal:  Neuropsychopharmacology       Date:  2018-06-19       Impact factor: 7.853

Review 9.  Microglia in depression: current perspectives.

Authors:  Xiaoning Jia; Zhihua Gao; Hailan Hu
Journal:  Sci China Life Sci       Date:  2020-10-14       Impact factor: 6.038

Review 10.  Immunoregulation and antidepressant effect of ketamine.

Authors:  Nan Zhang; Lihua Yao; Peilin Wang; Zhongchun Liu
Journal:  Transl Neurosci       Date:  2021-05-26       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.